Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Symphony Allegro

2006 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Developer of Alexza Pharmaceuticals' AZ-002 and AZ-004 products. The company was formed through a collaboration between Symphony Capital Partners and Alexza Pharmaceuticals to develop Alexza's AZ-002 Staccato Alprazolam and AZ-004 Staccato Loxapine programs. It supports AZ-002 through Phase IIb clinical trials for the treatment of panic attack in patients with panic disorder and AZ-004 through Phase IIb clinical trials for the treatment of acute agitation in patients with schizophrenia.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 7361 Calhoun Place
  • Suite 325
  • Rockville, MD 20855
  • United States

+1 (301) 000-0000

Symphony Allegro Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Symphony Allegro‘s full profile, request access.

Request full access to PitchBook

Symphony Allegro Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Symphony Allegro‘s full profile, request access.

Request full access to PitchBook